Jun 1, 2009
By:Allison Tsai
Montreal ? Actinic keratoses (AKs) present with intermittent expression, even in patients with extensive damage, according to an 11-month study presented at the recent Society for Investigative Dermatology meeting.
 |
Jun 1, 2009
By:Allison Tsai
Do you have a specific clinical pearl that you'd like to share with your colleagues? Dermatology Times wants to hear from you!
|
Jun 1, 2009
By:Allison Tsai
International report ? Researchers at the University of Nebraska Medical Center have discovered that a superfamily of molecules causes the progression and spread of melanoma. The study results are published in the British Journal of Cancer.
|
Jun 1, 2009
By:Allison Tsai
St. Louis ? A substance occurring from eczema-damaged skin may trigger asthma in children, according to a study published in PLoS Biology.
|
Jun 1, 2009
By:Allison Tsai
Hampton, N.H. ? The American Acne & Rosacea Society (AARS) has designated June 2009 as National Acne Awareness Month. The society hopes to educate healthcare providers about the treatment of acne through a series of live Webinars, according to a press release.
|
May 5, 2009
By:Allison Tsai
National report ? The American Acne & Rosacea Society (AARS) is offering a CME Webinar for dermatologists nationwide this June in conjunction with the first annual National Acne Awareness Month, according to a Society press release.
|
May 5, 2009
By:Allison Tsai
National report ? Allergan has officially launched its eyelash-growing product Latisse (bimatoprost ophthalmic solution 0.03 percent) to doctors who may be interested in prescribing it, according to Ophthalmology Times.
|
May 5, 2009
By:Allison Tsai
International report ? The Food and Drug Administration (FDA) approved the Biologics License Application for Dysport (botulinum toxin type A, Medicis, Ipsen) for the treatment of both cervical dystonia in adults and to temporarily improve the appearance of moderate-to-severe glabellar lines in adults younger than 65, Globe Newswire reports.
|
May 5, 2009
By:Allison Tsai
Washington ? Botox (botulinum toxin type A, Allergan) and similar products must carry a strong warning about the risk of severe complications if the toxin spreads in the body, according to the Food and Drug Administration (FDA).
|
| 
